Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Perou

Showing results (421-430 of 476) with videos related to

Pageof 48
Sort By:
Cell|April 17, 2012
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancerJames S Duncan, Martin C Whittle, Kazuhiro Nakamura, et al.
Breast Cancer Research : BCR|February 8, 2018
Frequency of breast cancer subtypes among African American women in the AMBER consortiumEmma H Allott, Joseph Geradts, Stephanie M Cohen, et al.
JAMA Oncology|April 27, 2023
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabCoralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, et al.
Cancer Research|June 6, 2013
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft modelsXiaomei Zhang, Sofie Claerhout, Aleix Prat, et al.
Biorxiv : the Preprint Server for Biology|October 28, 2024
Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinomeMichael P East, Robert W Sprung, Denis O Okumu, et al.
BMC Medical Genomics|October 6, 2012
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markersRoy R L Bastien, Álvaro Rodríguez-Lescure, Mark T W Ebbert, et al.
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Molecular & Cellular Proteomics : MCP|May 9, 2015
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast CancerChristian D Young, Lisa J Zimmerman, Daisuke Hoshino, et al.
Cell Reports. Medicine|June 6, 2025
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.
NPJ Breast Cancer|April 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, et al.
Pageof 48

Showing results (421-430 of 476) with videos related to

Sort By:
Pageof 48
Cell|April 17, 2012
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancerJames S Duncan, Martin C Whittle, Kazuhiro Nakamura, et al.
Breast Cancer Research : BCR|February 8, 2018
Frequency of breast cancer subtypes among African American women in the AMBER consortiumEmma H Allott, Joseph Geradts, Stephanie M Cohen, et al.
JAMA Oncology|April 27, 2023
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabCoralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, et al.
Cancer Research|June 6, 2013
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft modelsXiaomei Zhang, Sofie Claerhout, Aleix Prat, et al.
Biorxiv : the Preprint Server for Biology|October 28, 2024
Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinomeMichael P East, Robert W Sprung, Denis O Okumu, et al.
BMC Medical Genomics|October 6, 2012
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markersRoy R L Bastien, Álvaro Rodríguez-Lescure, Mark T W Ebbert, et al.
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Molecular & Cellular Proteomics : MCP|May 9, 2015
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast CancerChristian D Young, Lisa J Zimmerman, Daisuke Hoshino, et al.
Cell Reports. Medicine|June 6, 2025
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.
NPJ Breast Cancer|April 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, et al.
Pageof 48